News | August 03, 2024
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
